FDA panel to discuss Titan's Probuphine

FDA's Psychopharmacologic Drugs Advisory Committee will meet on March 21 to discuss an NDA for Probuphine buprenorphine from Titan Pharmaceuticals Inc. (OTCBB:TTNP) to treat opioid dependence. The PDU...